China vs. India: what kind of sparks are there between the big and powerful countries of generic drugs?

Source: Bio Valley on December 10, 2014, bilateral exchanges became more active after the high-level agreement between China and India that "China will expand the import of Indian drugs" S.V veerramani, President of the Indian Pharmaceutical Manufacturers Association, recently organized a delegation to visit China for exchange "I hope this trip will create more conditions and opportunities for each other's pharmaceutical trade, especially to strengthen exchanges with regulatory authorities, and lay a solid foundation for India's cost-effective brand generic drugs to enter China." S V veerramani told reporters New Delhi, Dec 7, at the scene of many conferences specially held for representatives of China and India, the contents of the talks involved pharmaceutical trade without exception Indian businessmen revealed their intention to attract Chinese pharmaceutical companies to invest and produce in India With the expiration of a large number of brand product patents, the mutual approach of the two big countries of generic drugs will promote the reconstruction of the pattern of the field of generic drugs "When the great power of generic drugs and the great power of generic drugs meet on a narrow road, this competition and cooperation competition can only realize itself in the international competition by strengthening international exchanges, self-cultivation and continuous improvement of the overall quality of products At present, the quality consistency evaluation of generic drugs in China is to improve the overall internal quality of domestic generic drugs In the future, brand generic drugs will be the main battleground for competition " Zhang Mingyu, senior vice president of China Chemical Pharmaceutical Industry Association, thinks With the continuous increase of medical insurance pressure in various countries, multinational pharmaceutical enterprises have arranged generic pharmaceutical market in the same place With Novartis building the largest generic pharmaceutical production base in China as the representative, Chinese pharmaceutical market gradually presents the situation of "international competition and localization" "With the change of industrial environment, China itself has been in an important position in the international market," a senior expert reminded It should be noted that in the past, there was no direct competition between domestic generic enterprises and multinational enterprises holding "sharp tools" of prescription drugs, and in the past, the domestic generic market competed the most fully through price In the future, foreign pharmaceutical enterprises will speed up the layout of China's market, and Indian enterprises with high-quality generic drugs will be very urgent "India's pharmaceutical industry has a total annual output value of US $30 billion, with rapid growth in diabetes, cardiovascular and psychiatric drugs India's pharmaceutical exports are 15 billion US dollars, and 11 billion US dollars of pharmaceutical products are mainly exported to European and American markets and other regulated markets " S V veerramani said that China India pharmaceutical trade, India is a big deficit, China is India's largest exporter of APIs, "we hope to have the opportunity to enter the Chinese market more quickly." Moreover, many "blockbuster" patents are about to expire The world's generic drug market has grown from $89 billion in 2007 to $172 billion in 2013, with an average annual growth rate of about 12% in recent years "Indian companies are taking a global linkage approach to reduce drug prices, research and development of new products, hoping to shorten the time to market generic drugs in China," said a senior executive of a pharmaceutical company in India On the other hand, the 2009 edition of the World Health Organization statistical yearbook shows that China has 6 varieties in the WHO procurement catalogue, while India has 194 Take a good step of internationalization, no matter inside or outside, the competition of high-quality generic drugs will not be avoided At present, China's pharmaceutical companies such as Jiangsu Lianhuan Pharmaceutical Co., Ltd are applying for approval documents similar to Viagra, which is just a microcosm of the shock in the generic pharmaceutical market caused by the global patent cliff "To participate in international competition, it is more important to reshape the spirit and the connotation of quality competition." Yu Xiong, vice president of China Pharmaceutical Industry Research Institute, said that domestic enterprises should dare to challenge international patents In the future, there will be endless preparations with high difficulty If they can't keep up with them, they won't have the chance to share the cake Secondly, we should pay attention to the research of major common key technologies of high-end preparations and the research and development of anti-cancer drugs urgently needed in clinic After all, quality is the key to survival How to achieve differentiation and self-improvement? Zhang Mingyu suggested: "the gap between the quality standards of domestic drugs and the quality standards of the same foreign varieties can be compared and analyzed, and the key evaluation indicators can be compared and studied pertinently The deficiencies in technology and process can be found, and the key development can be carried out, and the preparation process and prescription screening can be re studied The internal consumption of R & D strength should be avoided as much as possible in the scientific research project Of course, it also needs the support of bidding, pricing and other policies " Judging from the trend, the competition of bio generic drugs will be more intense "Antibody drug research is not facing the problem of" whether to set up the original research drug control ", but how to better design the experiment and set up the control, confirm the comparability between the two, and effectively control the research cost and shorten the research cycle." The above experts believe that on the basis of ensuring quality standards, marketing and technical marketing should do their homework Of course, policy support is essential China's drug registration and approval process is cumbersome, which directly lengthens the R & D and production process of generic drugs, and the long approval time makes drug companies anxious and helpless The situation is changing As for the low standard of generic drugs in the industry, the relevant national departments have clearly proposed that "there is a large gap between the quality of some generic drugs and the international advanced level" In the drug review process, CDE recently posted on its official website the first recruitment system for reviewers, and is exploring the purchase of third-party services "India's pharmaceutical industry still dominates the generic market when the global pharmaceutical market changes, mainly due to its focus on the research and development of generic drugs with complex technology and leading cost, seizing the opportunity of losing patent protection varieties, and shaping its advantages in specific treatment fields." Zhang Peng, vice president of Zhongshan kangfang biomedical Co., Ltd., said that cooperation and innovation with innovative cro to reduce costs would be an important step for domestic pharmaceutical enterprises.